CD14⁺CD16⁺⁺ “nonclassical” monocytes are associated with endothelial dysfunction in patients with coronary artery disease

Summary

Endothelial dysfunction and inflammation are key mechanisms of vascular disease. We hypothesised that heterogeneity of monocyte subpopulations may be related to the development of vascular dysfunction in coronary artery disease (CAD). Therefore, we examined the relationships between monocyte subsets (CD14⁺⁺CD16^– “classical – Mon1”, CD14⁺⁺CD16⁺ “intermediate – Mon2” and CD14⁺CD16⁺⁺ “nonclassical – Mon3”), endothelial function and risk factor profiles in 130 patients with CAD undergoing coronary artery bypass grafting. This allowed for direct nitric oxide (NO) bioavailability assessment using isometric tension studies ex vivo (acetylcholine; ACh- and sodium- nitropruside; SNP-dependent) in segments of internal mammary arteries. The expression of CD14 and CD16 antigens and activation markers were determined in peripheral blood mononuclear cells using flow cytometry. Patients with high CD14⁺CD16⁺⁺ “nonclassical” and low CD14⁺⁺CD16^- “classical” monocytes presented impaired endothelial function. High frequency of CD14⁺CD16⁺⁺ “nonclassical” monocytes was associated with increased vascular superoxide production. Furthermore, endothelial dysfunction was associated with higher expression of activation marker CD11c selectively on CD14⁺CD16⁺⁺ monocytes. Nonclassical and classical monocyte frequencies remained independent predictors of endothelial dysfunction when major risk factors for atherosclerosis were taken into account (β =0.18 p=0.04 and β =-0.19 p=0.03, respectively). In summary, our data indicate that CD14⁺CD16⁺⁺ “nonclassical” monocytes are associated with more advanced vascular dysfunction measured as NO-bioavailability and vascular reactive oxygen species production.

Keywords

Endothelial dysfunction - monocytes - ischaemic heart disease - atherosclerosis

• References

• 1 Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204
• 2 Libby P, Nahrendorf M, Swirski FK. Monocyte heterogeneity in cardiovascular disease. Semin Immunopathol 2013; 35: 553-562.
• 3 Nasir K, Guallar E, Navas-Acien A. et al. Relationship of monocyte count and peripheral arterial disease: results from the National Health and Nutrition Examination Survey 1999-2002. Arterioscler Thromb Vasc Biol 2005; 25: 1966-1971.
• 4 Gurm HS, Bhatt DL, Lincoff AM. et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG and EPISTENT trials. Heart 2003; 89: 1200-1204.
• 5 Rana JS, Boekholdt SM, Ridker PM. et al. Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med 2007; 262: 678-689.
• 6 Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterisation of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-2534.
• 7 Ziegler-Heitbrock L, Ancuta P, Crowe S. et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-80.
• 8 Weber C, Shantsila E, Hristov M. et al. Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups “Atherosclerosis & Vascular Biology” and “Thrombosis”. Thromb Haemost 2016; 116: 626-637.
• 9 Rogacev KS, Seiler S, Zawada AM. et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92.
• 10 Rogacev KS, Cremers B, Zawada AM. et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-1520.
• 11 Berg KE, Ljungcrantz I, Andersson L. et al. Elevated CD14++CD16- monocytes predict cardiovascular events. Circ Cardiovasc Genet 2012; 05: 122-131.
• 12 Tsujioka H, Imanishi T, Ikejima H. et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 2009; 54: 130-138.
• 13 Tapp LD, Shantsila E, Wrigley BJ. et al. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost 2012; 10: 1231-1241.
• 14 Krychtiuk KA, Kastl SP, Pfaffenberger S. et al. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis 2014; 237: 589-596.
• 15 Krychtiuk KA. et al. Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease. PLoS One 2015; 10: e0123367.
• 16 Rogacev KS, Heine GH. Human monocyte heterogeneity--a nephrological perspective. Nephrol Ther 2010; 06: 219-225.
• 17 Strauss-Ayali D, Conrad SM, Mosser DM. Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol 2007; 82: 244-252.
• 18 Aiello RJ, Bourassa PA, Lindsey S. et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 1518-1525.
• 19 Wenzel P, Knorr M, Kossmann S. et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011; 124: 1370-1381.
• 20 Wenzel P, Rossmann H, Muller C. et al. Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans. Eur Heart J 2015; 36: 3437-3446.
• 21 Guzik TJ, West NE, Black E. et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-90.
• 22 Guzik TJ, Mussa S, Gastaldi D, Sadowski J. et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-1662.
• 23 Antoniades C, Shirodaria C, Van Assche T. et al. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J Am Coll Cardiol 2008; 52: 158-165.
• 24 Piepoli MF, Hoes AW, Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-2381.
• 25 Wilk G, Osmenda G, Matusik P. et al. Endothelial function assessment in atherosclerosis: comparison of brachial artery flow mediated vasodilation and peripheral arterial tonometry. Pol Arch Med Wewn 2013; 123: 443-452.
• 26 Guzik TJ, Channon KM. Measurement of vascular reactive oxygen species production by chemiluminescence. Methods Mol Med 2005; 108: 73-89.
• 27 Mikolajczyk TP, Osmenda G, Batko B. et al. Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus 2016; 25: 18-27.
• 28 Heimbeck I, Hofer TP, Eder C. et al. Standardized single-platform assay for human monocyte subpopulations: Lower CD14+CD16++ monocytes in females. Cytometry A 2010; 77: 823-830.
• 29 Antoniades C, Bakogiannis C, Leeson P. et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124: 335-345.
• 30 Skiba DS, Nosalski R, Mikolajczyk TP. et al. Antiatherosclerotic effect of Ang- (1-7) non-peptide mimetic (AVE 0991) is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. Br J Pharmacol. 2016 Epub ahead of print.
• 31 Ghattas A, Griffiths HR, Devitt A. et al. Monocytes in coronary artery disease and atherosclerosis: where are we now?. J Am Coll Cardiol 2013; 62: 1541-1551.
• 32 Rogacev KS, Ulrich C, Blömer L. et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J 2010; 31: 369-376.
• 33 Amoruso A, Sola D, Rossi L. et al. Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study. Pharmacol Res 2016; 107: 308-314.
• 34 Wrigley BJ, Shantsila E, Tapp LD, Lip GY. CD14++CD16+ monocytes in patients with acute ischaemic heart failure. Eur J Clin Invest 2013; 43: 121-130.
• 35 Suzuki A, Fukuzawa K, Yamashita T. et al. Circulating intermediate CD14++CD16+monocytes are increased in patients with atrial fibrillation and reflect the functional remodelling of the left atrium. Europace 2017; 19: 40-47.
• 36 Tacke F, Ginhoux F, Jakubzick C. et al. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med 2006; 203: 583-597.
• 37 Mandl M, Schmitz S, Weber C, Hristov M. Characterisation of the CD14++CD16+ monocyte population in human bone marrow. PLoS One 2014; 09: e112140.
• 38 Sunderkötter C, Nikolic T, Dillon MJ. et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172: 4410-4417.
• 39 Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
• 40 Cros J, Cagnard N, Woollard K. et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-386.
• 41 Nahrendorf M, Swirski FK, Aikawa E. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-3047.
• 42 Shantsila E, Wrigley B, Tapp L. et al. Immunophenotypic characterisation of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J Thromb Haemost 2011; 09: 1056-1066.
• 43 Schmidl C, Renner K, Peter K. et al. Transcription and enhancer profiling in human monocyte subsets. Blood 2014; 123: e90-99.
• 44 Mehta NN, Reilly MP. Monocyte mayhem: do subtypes modulate distinct atherosclerosis phenotypes?. Circ Cardiovasc Genet 2012; 05: 7-9.
• 45 Bath PM, Gladwin AM, Martin JF. Human monocyte characteristics are altered in hypercholesterolaemia. Atherosclerosis 1991; 90: 175-181.
• 46 Sadhu C, Ting HJ, Lipsky B. et al. CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. J Leukoc Biol 2007; 81: 1395-1403.
• 47 Gahmberg CG, Valmu L, Fagerholm S, Kotovuori P, Ihanus E, Tian L. et al. Leukocyte integrins and inflammation. Cell Mol Life Sci 1998; 54: 549-555.
• 48 Pfluecke C, Berndt K, Wydra S. et al. Atrial fibrillation is associated with high levels of monocyte-platelet-aggregates and increased CD11b expression in patients with aortic stenosis. Thromb Haemost 2016; 115: 993-1000.
• 49 Wu H, Gower RM, Wang H. et al. Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation 2009; 119: 2708-2717.
• 50 Gower RM, Wu H, Foster GA. et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011; 31: 160-166.
• 51 Foster GA, Gower RM, Stanhope KL. et al. On-chip phenotypic analysis of inflammatory monocytes in atherogenesis and myocardial infarction. Proc Natl Acad Sci USA 2013; 110: 13944-13949.
• 52 Fink K, Busch HJ, Bourgeois N. et al. Mac-1 directly binds to the endothelial protein C-receptor: a link between the protein C anticoagulant pathway and inflammation?. PloS one 2013; 08: e53103.
• 53 Zaldivia MT, Rivera J, Hering D. et al. Renal Denervation Reduces Monocyte Activation and Monocyte-Platelet Aggregate Formation: An Anti-Inflammatory Effect Relevant for Cardiovascular Risk. Hypertension 2017; 69: 323-331.